Oruka's ORKA-001 posts 61% complete skin clearance in Phase II psoriasis trial
Start here
Oruka Therapeutics has reported results from EVERLAST-B, a Phase II psoriasis trial of ORKA-001, its long-acting IL-23 inhibitor. In the highest dose group, 61% of patients achieved complete skin clearance at week 16, and 86% achieved at least a 90% improvement in PASI scores. The results strengthen the case that long-acting IL-23 inhibitors can deliver higher skin clearance rates with less frequent dosing than current options. The data drove one of the week's largest clinical data-related stock gains. Open questions include how the efficacy profile holds up in later-stage trials and what the final dosing interval will be.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biocentury.comOruka raises efficacy expectations for long-acting IL-23 inhibitors
Oruka Therapeutics reported results from the Phase II EVERLAST-B psoriasis trial of ORKA-001: 61% of patients in the highest dose group achieved complete skin clearance at week 16, and 86% achieved at least a 90% improvement in PASI. The data strengthen the prospect that long-acting IL-23 inhibitors could deliver higher skin clearance rates with less frequent dosing, and drove one of the week's largest clinical data-related stock gains.
Heat trend for this story
Heat now 6·Peak in the comparable set 10 (Oct 28 01:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.